Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer Active Not Recruiting Phase 3 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0075646 (Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02296125AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerTreatment